Wintermute Biomedical presented ZosterEase clinical trial results at Asia Bio Partnering Forum, connecting with pharmaceutical, biotechnology and investment leaders from across the Asia-Pacific region.
Singapore | 1–2 September 2026
Wintermute's Executive Chairman, Mr Paul Field, presented the Company in Singapore, participating in a programme of partnering meetings and discussions with pharmaceutical, biotechnology and investment organisations.
These discussions provide an opportunity to introduce and further advance awareness of Solexan™, Wintermute's investigational, first-in-class topical antiviral therapy being developed for the treatment of herpes zoster (shingles).
Following the successful completion of our Phase Ib clinical study, Wintermute is progressing plans for the next stage of Solexan™ clinical development while continuing to explore strategic partnerships that could support its future development and commercialisation.
Participation in the Asia Bio Partnering Forum forms part of Wintermute Biomedical's broader international business development strategy and our continued engagement with the Asia-Pacific pharmaceutical and biotechnology community.
We look forward to the conversations ahead and to building relationships with organisations that share our ambition to advance innovative therapies addressing significant unmet medical needs.